Calidi Biotherapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
AMEX
George Peoples, a Director of Calidi Biotherapeutics, Inc., received 4,000 shares of common stock on August 17, 2026.
AMEX
Scott Leftwich, a Director of Calidi Biotherapeutics, Inc., received 4,000 shares of common stock on August 17, 2026.
AMEX
Alan R. Stewart, a Director of Calidi Biotherapeutics, Inc., received 4,000 shares of common stock on August 17, 2026.
AMEX
Andrew C. Jackson, Chief Financial Officer of Calidi Biotherapeutics, Inc., received 14,000 shares of common stock on August 17, 2026.
AMEX
James A Schoeneck, a Director of Calidi Biotherapeutics, Inc., received 5,000 shares of common stock on August 17, 2026.
AMEX
Eric E Poma, Chief Executive Officer of Calidi Biotherapeutics, Inc., received 32,000 shares of common stock on August 17, 2026.
AMEX
Santidrian Antonio Fernandez, Chief Scientific Officer of Calidi Biotherapeutics, Inc., received 16,000 shares of common stock on August 17, 2026.
AMEX
Corazon (Corsee) D. Sanders, a Director of Calidi Biotherapeutics, Inc., received 6,000 shares of common stock on August 17, 2026.
AMEX
Calidi Biotherapeutics Director Allan Camaisa sold 850 shares of common stock for $1.455 per share for estate and tax planning purposes.
AMEX
Calidi Biotherapeutics' CEO, Eric Poma, was granted 10,000 incentive stock options at an exercise price of $1.58, vesting over a multi-year period.
AMEX
Calidi Biotherapeutics' Chief Scientific Officer, Antonio Fernandez Santidrian, was granted 35,000 incentive stock options at an exercise price of $1.58.
AMEX
Calidi Biotherapeutics' Chief Financial Officer, Andrew C. Jackson, received a grant of 30,000 incentive stock options at an exercise price of $1.58.
AMEX
Calidi Biotherapeutics Director James A. Schoeneck purchased 75,000 common shares and warrants in a public offering on August 21, 2025, for $2.00 per unit.
AMEX
Calidi Biotherapeutics CEO Eric Poma acquired 25,000 common shares and accompanying warrants in a public offering.
AMEX
Calidi Biotherapeutics Director Scott Leftwich acquired 125,000 shares of common stock and 125,000 warrants in a public offering, increasing his direct beneficial ownership.
AMEX
Calidi Biotherapeutics' CFO, Andrew C. Jackson, acquired 2,500 common shares and accompanying warrants in a public offering on August 21, 2025, for $2.00 per unit.
AMEX
Calidi Biotherapeutics, Inc. Director James A. Schoeneck was granted non-qualified stock options to purchase 164,493 shares of common stock at an exercise price of $0.70 per share.
AMEX
Calidi Biotherapeutics, Inc. Director Alan R. Stewart was granted 137,078 non-qualified stock options at an exercise price of $0.70 per share, vesting monthly over one year.
AMEX
Calidi Biotherapeutics, Inc. Director George Peoples was granted non-qualified stock options to purchase 137,078 shares of common stock at an exercise price of $0.70 per share.
AMEX
Calidi Biotherapeutics, Inc. Director Scott Leftwich was granted non-qualified stock options to purchase 137,078 shares of common stock at an exercise price of $0.70 per share.
AMEX
Eric Poma, CEO of Calidi Biotherapeutics, receives a grant of 726,412 stock options as an inducement award.
AMEX
Alan R. Stewart, a director at Calidi Biotherapeutics, reported the acquisition and disposal of common stock on December 31, 2024, according to a Form 4 filing with the SEC.
AMEX
Director Scott Leftwich acquired 11,684 shares of Calidi Biotherapeutics common stock through a grant of restricted stock units (RSUs) on December 31, 2024.
AMEX
Calidi Biotherapeutics CEO and Chairman Allan Camaisa sold 10,000 shares of common stock at $1.62 per share for tax planning purposes.
AMEX
Scott Leftwich, a director at Calidi Biotherapeutics, acquired non-qualified stock options for 20,217 shares of common stock.
AMEX
Director George Peoples acquired non-qualified stock options for 20,217 shares of Calidi Biotherapeutics common stock.
AMEX
James A. Schoeneck, a director of Calidi Biotherapeutics, acquired non-qualified stock options for 20,217 shares of common stock.
AMEX
Director Alan R. Stewart acquired non-qualified stock options for 20,217 shares of Calidi Biotherapeutics common stock.
AMEX
Calidi Biotherapeutics CEO Allan Camaisa acquired 70,155 shares of common stock in lieu of cash repayments for payables owed to him.
AMEX
Director George Peoples of Calidi Biotherapeutics was granted 30,904 non-qualified stock options on July 1, 2024, according to a Form 4 filing.